Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026. Read More
Đọc thêm từ Tài chính
Instant View: Markets cheer deal but see staying elevated
Close Top Stories Asia East Asia Singapore World Commentary CNA Explains Sustainability Business Sport Latest News Insider TODAY Big Read Up Close In Pixels Ground Up Voices Adulting Mental Health Matters Watch Live TV News Reports Documentaries & Shows TV Schedule Listen CNA938
Oil falls over 4% after US and Iran reach peace deal, to reopen Strait of Hormuz
Brent crude fell 4.02 per cent to US$83.82 as at 6.03m Singapore time.
